FDA approves Auvelity for Alzheimer’s disease-related agitation

The U.S. Food and Drug Administration has approved the expanded use of Axsome Therapeutics’ Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release…

Continue Reading


News Source: medicalxpress.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *